Literature DB >> 16368548

Matrix metalloproteinases (MMPs) in health and disease: an overview.

Charles J Malemud1.   

Abstract

Matrix metalloproteinases (MMPs) are members of an enzyme family that require a zinc ion in their active site for catalytic activity. MMPs are critical for maintaining tissue allostasis. MMPs are active at neutral pH and can therefore catalyze the normal turnover of extracellular matrix (ECM) macromolecules such as the interstitial and basement membrane collagens, proteoglycans such as aggrecan, decorin, biglycan, fibromodulin and versican as well as accessory ECM proteins such as fibronectin. Members of the MMP family include the "classical" MMPs, the membrane-bound MMPs (MT-MMPs) the ADAMs (a disintegrin and metalloproteinase; adamlysins) and the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif). There are more than 20 members in the MMP and ADAMTS family including the collagenases, gelatinases, stromelysins, some elastases and aggrecanases. Adamlysins are membrane-bound MMPs that also degrade aggrecan, but more importantly, one ADAM family member (i.e.ADAM-17) is a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE) that activates pro-TNF-alpha. Most of the MMPs are synthesized as inactive latent enzymes. Conversion to the active enzyme is generally mediated by activator systems that include plasminogen activator or the pro-hormone convertase, furin. MMP activity is regulated by a group of endogenous proteins, called, tissue inhibitor of metalloproteinases (TIMPs) that bind to active and alternative sites of the activated MMP. Significant advances have occurred in the understanding of the regulation of MMPs, ADAMs and ADAMTSs gene expression. In addition, development of MMP inhibitors to study MMP structure/function relationships spawned many studies to determine the effectiveness of MMP inhibitors in regulating abnormal connective tissue turnover. In addition, development of MMP null mice carrying specific MMP deletions has provided an opportunity to explore the role of MMPs in normal development as well as in such diverse conditions and diseases as skeletal dysplasias, coronary artery and heart disease, arthritis, cancer, and brain disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368548     DOI: 10.2741/1915

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  219 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

2.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

Review 3.  ADAMTS proteases: key roles in atherosclerosis?

Authors:  Rebecca C Salter; Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2010-07-22       Impact factor: 4.599

4.  Association of matrix metalloproteinase gene polymorphisms with refractive error in Amish and Ashkenazi families.

Authors:  Robert Wojciechowski; Joan E Bailey-Wilson; Dwight Stambolian
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

5.  Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking.

Authors:  Michel C Van den Oever; Bart R Lubbers; Natalia A Goriounova; Ka W Li; Roel C Van der Schors; Maarten Loos; Danai Riga; Joost Wiskerke; Rob Binnekade; M Stegeman; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Taco J De Vries; Sabine Spijker
Journal:  Neuropsychopharmacology       Date:  2010-06-30       Impact factor: 7.853

6.  Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line.

Authors:  Evan C Meszaros; Wissam Dahoud; Sam Mesiano; Charles J Malemud
Journal:  Integr Mol Med       Date:  2015-08-08

7.  Expression of matrix metalloproteinases during experimental Candida albicans keratitis.

Authors:  Xiaoyong Yuan; Bradley M Mitchell; Kirk R Wilhelmus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02       Impact factor: 4.799

Review 8.  Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.

Authors:  Sajad Sarvari; Faezeh Moakedi; Emily Hone; James W Simpkins; Xuefang Ren
Journal:  Metab Brain Dis       Date:  2020-04-15       Impact factor: 3.584

9.  Increased receptor activator of nuclear factor κβ ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitro.

Authors:  Ji-Zhou Zeng; Zhen-Zhong Wang; Li-Feng Ma; Hai Meng; Hao-Miao Yu; Wen-Hao Cheng; Ya-Kui Zhang; Ai Guo
Journal:  Exp Ther Med       Date:  2016-08-31       Impact factor: 2.447

10.  Tissue inhibitor of matrix metalloproteinase-3 levels in the extracellular matrix of lung, kidney, and eye increase with age.

Authors:  Anne M Macgregor; Charles G Eberhart; Mostafa Fraig; Jie Lu; Marc K Halushka
Journal:  J Histochem Cytochem       Date:  2008-10-27       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.